Vanguard Group’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-3,840,786
| Closed | -$106M | – | 4563 |
|
|
2021
Q2 | $106M | Buy |
3,840,786
+160,514
| +4% | +$3.15M | ﹤0.01% | 1972 |
|
|
2021
Q1 | $60.7M | Buy |
3,680,272
+136,432
| +4% | +$3.11M | ﹤0.01% | 2210 |
|
|
2020
Q4 | $65.3M | Sell |
3,543,840
-95,577
| -3% | -$1.71M | ﹤0.01% | 2063 |
|
|
2020
Q3 | $49.5M | Buy |
3,639,417
+964,165
| +36% | +$14.9M | ﹤0.01% | 2020 |
|
|
2020
Q2 | $47.9M | Buy |
2,675,252
+930,638
| +53% | +$14M | ﹤0.01% | 2031 |
|
|
2020
Q1 | $17.4M | Buy |
1,744,614
+40,404
| +2% | +$331K | ﹤0.01% | 2363 |
|
|
2019
Q4 | $13.9M | Sell |
1,704,210
-418,620
| -20% | -$3.86M | ﹤0.01% | 2699 |
|
|
2019
Q3 | $21M | Buy |
2,122,830
+597,923
| +39% | +$5.65M | ﹤0.01% | 2471 |
|
|
2019
Q2 | $19.3M | Buy |
1,524,907
+680,330
| +81% | +$7.17M | ﹤0.01% | 2527 |
|
|
2019
Q1 | $8.61M | Buy |
844,577
+443,083
| +110% | +$3.4M | ﹤0.01% | 2908 |
|
|
2018
Q4 | $3.01M | Buy |
401,494
+113,572
| +39% | +$832K | ﹤0.01% | 3258 |
|
|
2018
Q3 | $2.88M | Buy |
+287,922
| New | +$3.35M | ﹤0.01% | 3413 |
|
Vanguard Group's TBIO Position: Q3 2021 in Review
Vanguard Group sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 3,840,786 shares — an estimated $106M sold.
Vanguard Group first reported a position in TBIO in Q3 2018 and held it in 12 quarters. The position peaked at $106M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Vanguard Group reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Vanguard Group sold 3,840,786 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $106M.
- Vanguard Group first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
- Vanguard Group's Translate Bio, Inc. Common Stock position peaked at $106M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Vanguard Group's 13F filing for Q3 2021, filed 12 Nov 2021.